B
MRKR icon

Bailard’s Marker Therapeutics MRKR Stock Holding History

Bailard’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,100
Closed -$261K – 582
2019
Q3 		$261K Buy
5,100
+1,000
+24% +$59.1K 0.02% 427
2019
Q2 		$325K Buy
4,100
+1,000
+32% +$59.4K 0.02% 395
2019
Q1 		$205K Buy
3,100
+1,000
+48% +$58.4K 0.01% 484
2018
Q4 		$117K Buy
+2,100
New +$153K 0.01% 484

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Bailard's MRKR Position: Q4 2019 in Review

Bailard sold out of Marker Therapeutics (MRKR) in Q4 2019, closing a stake of 5,100 shares — an estimated $261K sold.

Bailard first reported a position in MRKR in Q4 2018 and held it in 4 quarters. The position peaked at $325K in Q2 2019. 65 funds tracked by Wall St. Rank hold MRKR as of Q4 2019.

  • Bailard reported no remaining Marker Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Bailard sold 5,100 Marker Therapeutics shares in Q4 2019, an estimated $261K.
  • Bailard first reported a position in Marker Therapeutics in Q4 2018 and held it in 4 quarters.
  • Bailard's Marker Therapeutics position peaked at $325K in Q2 2019.
  • 65 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2019.

Based on Bailard's 13F filing for Q4 2019, filed 31 Jan 2020.